J
Jonas Mattsson
Researcher at University of Toronto
Publications - 280
Citations - 6714
Jonas Mattsson is an academic researcher from University of Toronto. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 43, co-authored 242 publications receiving 5916 citations. Previous affiliations of Jonas Mattsson include University of Oslo & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Graft failure in the modern era of allogeneic hematopoietic SCT
Richard F. Olsson,Richard F. Olsson,Mats Remberger,Mats Remberger,Marie Schaffer,D M Berggren,Britt-Marie Svahn,Jonas Mattsson,Jonas Mattsson,O Ringdén,O Ringdén +10 more
TL;DR: Graft failure was only associated with inferior survival in malignant disease, and non-malignant disorders, HLA match, conditioning intensity, immunosuppression regimen and cell dose all influenced graft failure risk.
Journal ArticleDOI
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
S Carlens,O Ringdén,M Remberger,Berit Lönnqvist,Hans Hägglund,S. Klaesson,Jonas Mattsson,Britt-Marie Svahn,Jacek Winiarski,Per Ljungman,Johan Aschan +10 more
TL;DR: Among 551 consecutive recipients of allogeneic bone marrow transplants, 451 survived more than 3 months and were evaluated for chronic graft-versus-host disease (GVHD), and high recipient age was the single most important risk factor (P < 0.001).
Journal ArticleDOI
Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.
Per Ljungman,Johan Aschan,Ilona Lewensohn-Fuchs,S Carlens,Kajsa Larsson,Berit Lönnqvist,Jonas Mattsson,Elda Sparrelid,Jacek Winiarski,Olle Ringdén +9 more
TL;DR: Preemptive therapy based on polymerase chain reaction for CMV DNA was associated with reduced risks forCMV disease, CMV-associated death, and TRM, whereas other prophylactic modalities did not give additional benefit.
Journal ArticleDOI
Graft failure after allogeneic hematopoietic cell transplantation.
TL;DR: Graft failure is a significant complication following allogeneic hematopoietic cell transplantation (alloHCT) and is increased in HLA-mismatched graftS, unrelated grafts, T cell-replete transplants, sensitized patients, and in patients treated with reduced-intensity conditioning (RIC).
Journal ArticleDOI
No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study.
TL;DR: The use of a moderate dose of steroids during 4 months after transplantation has no important influence on bone mass during the first year after renal transplantation, and both regimens prevented accelerated bone loss.